Results 261 to 270 of about 276,777 (390)

Evidence and Cost Effectiveness Requirements for Recommending New Biomarkers. [PDF]

, 2015
Collinson, P
core   +1 more source

Pantethine therapy dramatically rescues end‐stage failing heart in a patient with deficiency of coenzyme A biosynthesis

ESC Heart Failure, EarlyView.
Violette Goetz, Bruno Lefort, Magalie Barth, Naïg Gueguen, Céline Bris, Emmanuelle Blanchard, Isabelle Benz‐de Bretagne, Hélène Blasco, Marine Tardieu, François Labarthe   +9 more
wiley   +1 more source

Clinical impact of follow‐up endomyocardial biopsy in myocarditis during or after immune‐suppressive therapy

ESC Heart Failure, EarlyView.
Results and clinical implication of repeat endomyocardial biopsy (EMB). Abstract Aims While the diagnostic role of endomyocardial biopsy (EMB) in myocarditis is unquestioned, little is known about its indications and clinical value during long‐term follow‐up.
Anna Baritussio, Andrea Silvio Giordani, Stefania Rizzo, Cristina Vicenzetto, Monica De Gaspari, Elisa Carturan, Giuseppe Toscano, Federico Scognamiglio, Giuseppe Tarantini, Sabino Iliceto, Cristina Basso, Renzo Marcolongo, Alida Linda Patrizia Caforio   +12 more
wiley   +1 more source

Nanoparticulate Copper Cluster-Mediated Biosensing of Cardiac Biomolecular Markers. [PDF]

Biosensors (Basel)
Nair LV, Wheeler J, Ha Y, Jones KM, Jones J, Thomas V.   +5 more
europepmc   +1 more source

Role of serum cardiac Troponin-I for risk stratification in first attack in acute myocardial infarction

, 1970
Md Sahabuddin Joarder, Md Jafarullah, Ahmed Moinuddin   +2 more
openalex   +2 more sources

Angiotensin receptor‐neprilysin inhibitors in concurrent heart failure with reduced ejection fraction and kidney failure

ESC Heart Failure, EarlyView.
Abstract Aims Angiotensin receptor‐neprilysin inhibitor (ARNI) therapy has demonstrated improved outcomes in heart failure with reduced ejection fraction (HFrEF). However, its benefits in patients with concomitant kidney failure undergoing replacement therapy remain uncertain. Methods and results Using the National Health Insurance Service database, we
Mi‐Hyang Jung, Dong‐Hyuk Cho, Jimi Choi, Mi‐Na Kim, Chan Joo Lee, Jung‐Woo Son, Yaeni Kim, Jong‐Chan Youn, Byung‐Su Yoo   +8 more
wiley   +1 more source

Evaluation of the utility of cardiac biomarkers for risk stratification in patients with lower extremity artery disease: A retrospective study. [PDF]

PLoS One
Schweiger L, Raggam RB, Toth-Gayor G, Jud P, Avian A, Nemecz V, Gütl K, Brodmann M, Gary T.   +8 more
europepmc   +1 more source

Structure of the Regulatory proteins-Tropomyosin and Troponin.

, 1979
Hitoshi Ueno, Tatsuo Ooi
openalex   +2 more sources

The Mayo ATTR‐CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis

European Journal of Heart Failure, EarlyView.
Proposed algorithm to screen for transthyretin cardiac amyloidosis (ATTR‐CA). AL‐CA, immunoglobulin light‐chain cardiac amyloidosis; AMYLI, AMYLoidosis Index; AUC, area under the curve; IWT, increased wall thickness; LVEF, left ventricular ejection fraction; PYP, pyrophosphate.
Giovanni Battista Bonfioli, Daniela Tomasoni, Giuseppe Vergaro, Vincenzo Castiglione, Marianna Adamo, Iacopo Fabiani, Victor Loghin, Carlo Mario Lombardi, Alessio Nicolai, Marco Metra, Michele Emdin, Alberto Aimo   +11 more
wiley   +1 more source

Cardiac Troponin: Fragments of the Future? [PDF]

JACC Adv
McGrath S, Alaour B, Kampourakis T, Marber M.   +3 more
europepmc   +1 more source